What does biopharma systems — goodwill mean?

This metric represents the excess purchase price paid for acquisitions attributed to the BioPharma Systems segment over the fair value of its identifiable net assets. It serves as a balance sheet indicator of the segment's historical inorganic growth strategy and the premium paid for market share, technology, or synergies. Significant goodwill balances highlight the segment's reliance on past acquisitions to maintain its competitive position.

Becton, Dickinson and Company BDX BioPharma Systems — Goodwill

Other segment segments

Interventional

$12.76B+0.5%

Medical Essentials

$7.01B—

Connected Care

$6.1B—

Similar metrics at other companies

MLABBiopharmaceutical Development — Goodwill

$49.67M+3.0%

WAT

WATBiosciences — Goodwill

$3.8B—

LHBiopharma Laboratory Services — Goodwill

$1.35B—

BAXPharmaceuticals — Goodwill

$569M+2.2%

LHBiopharma Laboratory Services — Goodwill acquired, excluding measurement period adjustments

$0—

TMOLaboratory Products and Biopharma Services — Goodwill

$24.23B+1.9%

Other financials

Income statement

See full

Revenue$4.7B+5.2%

Gross profit$2.2B+15.7%

Operating income$93.0M-75.7%

Net income-$311.0M-201%

EPS (diluted)-$1.11-204%

Balance sheet

See full

Cash & equivalents$1.0B+49.0%

Total debt$14.7B-16.8%

Total equity$24.1B-4.4%

Total assets$50.8B-6.7%

Cash flow

See full

Operating cash flow$671.0M—

CapEx$125.0M+9.6%

Free cash flow$546.0M—

Valuation

See full

Market cap$42.96B-12.6%

Enterprise value$56.65B-14.0%

P/E37.8×+6.7×

P/S2×-0.4×

Profitability

See full

Gross margin46.8%+2.5pp

Operating margin10.4%+0.1pp

Net margin5.3%-2.1pp

FCF margin16.4%—

Returns & leverage

See full

Return on equity4.6%-1.3pp

Debt / equity0.6×-0.1×

Current ratio0.9×-0.2×

Where this comes from

Reported directly by Becton, Dickinson and Company in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Becton, Dickinson and Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Becton, Dickinson and Company's biopharma systems — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Becton, Dickinson and Company's biopharma systems — goodwill?: Becton, Dickinson and Company (BDX) reported biopharma systems — goodwill of $96M in Q1 2026.
What does biopharma systems — goodwill mean?: This metric represents the excess purchase price paid for acquisitions attributed to the BioPharma Systems segment over the fair value of its identifiable net assets. It serves as a balance sheet indicator of the segment's historical inorganic growth strategy and the premium paid for market share, technology, or synergies. Significant goodwill balances highlight the segment's reliance on past acquisitions to maintain its competitive position.